Tuesday, August 19, 2014
Stemedica International Announces Pre-clinical Data of its Alzheimer’s Study
The First Pre-clinical Mouse Study Using Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Shows Over 30-Percent Decrease in Amyloid Beta (Abeta) Plaques
Epalinges, Switzerland – Aug. 19, 2014 – Stemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30-percent decrease in amyloid beta (Abeta) plaques in the brain of transgenic animals treated with Stemedica itMSCs compared to the control group that were treated with lactated Ringer’s solution (LRS).
“Pre-clinical results show Stemedica International’s treatment reduces the amount of plaque as much as the best drug candidates to manage Abeta amyloidosis,” says Stemedica International’s Chief Scientist Tristan Bolmont, Ph.D. “Most importantly, our itMSC treatment did not result in side effects, such as cerebral amyloid angiopathy and micro-hemorrhages.”
These promising results were achieved during a two-year, intensive, pre-clinical research project supported by a grant from the Swiss Commission for Technology and Innovation (CTI). The research was conducted at the Laboratoire d’Optique Biomedicale and headed by Professor Theo Lasser at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland.
The results were presented at the Alzheimer’s Association International Conference in Copenhagen, Denmark, on July 14, 2014. In addition, Dr. Bolmont will share the findings during his talk at the Stem Cells Regenerative Medicine Congress 2014 in Boston, Massachusetts, on Sept. 15 at 2:30 p.m. ET.
“The combination of safety and efficacy of Stemedica’s itMSCs clears the pathway for Stemedica International to file an IND application with the FDA for clinical trials,” says Stemedica International’s General Manager Alexei Lukashev, Ph.D. “We hope our stem cell treatment can halt or slow down the progression of Alzheimer’s disease and, maybe, have some reverse effect on the damage caused by Alzheimer’s disease and other forms of dementia, which the Alzheimer’s Disease Institute estimates afflicts more than 44 million people worldwide today.”
Only Stemedica International’s therapies feature itMSCs that are exclusively licensed from the parent company Stemedica Cell Technologies, Inc. Unlike other MSCs – which are grown under normoxic conditions – Stemedica’s bone-marrow-derived, allogeneic itMSCs are unique because they are grown under hypoxic conditions. In vitro experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to other MSCs, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.
go to site Canadian pharmacy discount do my thesis http://medinahealthcare.org/where-can-i-buy-viagra/ http://styronsquareapartments.com/healthnet-viagra-9654/ viagra pills online https://behereforme.org/levitra-for-sale/ how can i pay someone to write my essay order viagra without prescription how long should my college application essay be http://www.healmyptsd.com/erectile/cialis-dailies/100/ need someone to write essay in southeastern colorado hongkong viagra viagra and analogs go to site https://roanokechowan.edu/pharmacy/viagra-low-price/21/ click here get link https://www.asle.org/institute/environmental-science-essay/19/ generic viagra cialis viagra oral jelly doxycycline kidney disease writing zip code click http://naturesknockout.com/store.php?pill=how-long-does-viagra-last-for&es=40 thesis examples for a research paper http://styronsquareapartments.com/buy-on-line-proscar-usa-11869/ metformin wonder drug About Stemedica International S.A.
Founded in Epalinges, Switzerland, in 2008, Stemedica International S.A. is a global biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has an exclusive license to manufacture and distribute the parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease and vascular dementia indications. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
Ashleigh Erwin, Media Representative
The Townsend Team
David Cheatham, MBA, Business Manager
Stemedica International S.A.
+41 (0)21 651 9050